Blood pressure reduction

Clinical Trials in Heart Disease: A Companion to Braunwald's Heart Disease

Volumn , Issue , 2004, Pages 282-296

  Whelton, Paul K ^a   He, Jiang ^b  

^a TULANE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^b TULANE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84904027411     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-7216-0408-4.50028-7     Document Type: Chapter

References (92)

1. Whelton PK, He J, Klag MJ Blood pressure in westernized populations. Textbook of Hypertension 1994, 11-21. Blackwell Scientific Publications, Ltd., Oxford. J.D. Swales (Ed.).
2. Poulter NR, Sever PS Low blood pressure populations and the impact of rural-urban migration. Textbook of Hypertension 1994, 22-36. Blackwell Scientific Publications, Ltd., Oxford. J.D. Swales (Ed.).
3. He J, Klag MJ, Whelton PK, et al. Migration, blood pressure pattern, and hypertension. Am J Epidemiol 1991, 134:1085-1101.
4. Poulter NR, Khaw KT, Hopwood BEC, et al. The Kenyan Luo migration study: Observations on the initiation of a rise in blood pressure. Br Med J 1990, 300:967-972.
5. Burt V, Whelton PK, Roccella E, et al. Prevalence of hypertension in the US adult population: Results from the Third National Health and Nutrition Examination Survey, 1988-91. Hypertension 1995, 25:305-313.
6. Whelton PK Epidemiology of hypertension. Lancet 1994, 344:101-106.
7. Stamler J, Stamler R, Neaton JD Blood pressure, systolic and diastolic, and cardiovascular risks: U.S. population data. Arch Intern Med 1993, 153:598-615.
8. MacMahon S, Peto R, Cutler J, et al. Blood pressure, stroke, and coronary heart disease. I. Prolonged differences in blood pressure. prospective observational studies corrected for the regression dilution bias. Lancet 1990, 335:765-774.
9. Whelton PK, Perneger TV, He J, et al. The role of blood pressure as a risk factor for renal disease: A review of the epidemiologic evidence. J Human Hypertens 1996, 10:683-689.
10. Klag MJ, Whelton PK, Randall BL, et al. A prospective study of blood pressure and incidence of end-stage renal disease in 332,544 men. N Engl J Med 1996, 334:13-18.
11. Working Group on Primary Prevention of Hypertension Report of the National High Blood Pressure Education Program Working Group on Primary Prevention of Hypertension. Arch Intern Med 1993, 153:186-208.
12. Harrington M, Kincaid-Smith P, McMichael J Results of treatment of malignant hypertension. Br Med J 1959, 2:969-989.
13. Mohler ER, Freis ED Five-year survival of patients with malignant hypertension treated with antihypertensive agents. Am Heart J 1960, 60:329-335.
14. Bjork S, Sannerstedt R, Falkheden T, et al. The effect of active drug treatment in severe antihypertensive disease. Acta Med Scand 1961, 169:673-689.
15. Hamilton M, Thompson EW, Wisniewski TKM The role of blood pressure control in preventing complications of hypertension. Lancet 1964, 1:235-238.
16. Wolff FW, Lindeman RD Effects of treatment in hypertension: Results of a controlled study. J Chron Dis 1966, 19:227-240.
17. Veterans Administration Cooperative Study Group on Antihypertensive Agents Effects of treatment on morbidity in hypertension: Results in patients with diastolic blood pressure averaging 115 through 129 mm Hg. JAMA 1967, 202:1028-1034.
18. Veterans Administration Cooperative Study Group on Antihypertensive Agents Effects of treatment on morbidity in hypertension: II. Results in patients with diastolic blood pressure averaging 90 through 114 mm Hg. JAMA 1970, 213:1143-1152.
19. Carter AB Hypotensive therapy in stroke survivors. Lancet 1970, 1:485-489.
20. Barraclough M, Bainton D, Joy MD, et al. Control of moderately raised blood pressure: Report of a co-operative randomized controlled trial. BMJ 1973, 3:434-436.
21. Hypertension-Stroke Cooperative Study Group Effect of antihypertensive treatment on stroke recurrence. JAMA 1974, 229:409-418.
22. US Public Health Service Hospitals Cooperative Study Group Treatment of mild hypertension: Results of a ten-year intervention trial. Circ Res 1977, 40:I-98-I-105.
23. Veterans Administration National Heart, Lung, and Blood Institute Study Group for Cooperative Studies on Antihypertensive Therapy Mild Hypertension (Perry HM): Treatment of mild hypertension: Preliminary results of a two-year feasibility trial. Circ Res 1977, 40(1):180-187.
24. Veterans Administration National Heart, Lung, and Blood Institute Study Group for Evaluating Treatment in Mild Hypertension Evaluation of drug treatment in mild hypertension: VA-NHLBI Feasibility Trial. Ann NY Acad Sci 1978, 304:267-288.
25. Hypertension Detection and Follow-up Program Cooperative Group Five-year findings of the hypertension detection and follow-up program: I. Reduction in mortality of persons with high blood pressure, including mild hypertension. JAMA 1979, 242:2562-2571.
26. Hypertension Detection and Follow-up Program Cooperative Group Five-year findings of the hypertension detection and follow-up program. II. Mortality by race-sex and age. JAMA 1979, 242:2572-2577.
27. Helgeland A Treatment of mild hypertension: A five-year controlled drug trial. The Oslo Study. Am J Med 1980, 69:725-732.
28. Leren P, Helgeland A Oslo Hypertension Study. Drugs 1986, 31(1):41-45.
29. Australian National Blood Pressure Study Management Committee The Australian therapeutic trial in mild hypertension. Lancet 1980, i:1261-1267.
30. Medical Research Council Working Party MRC trial of treatment of mild hypertension: principal results. Br Med J 1985, 291:97-104.
31. Amery A, Birkenhager W, Brixko P, et al. Mortality and morbidity results from the European working party on high blood pressure in the elderly trial. Lancet 1985, i:1349-1354.
32. Cooper J, Warrender TS Randomized trial of treatment of hypertension in elderly patients in primary care. Br Med J 1986, 293:1145-1151.
33. SHEP Cooperative Research Group Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension: Final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA 1991, 265:3255-3264.
34. Dahlof B, Lindholm LH, Hansson L, et al. Morbidity and mortality in the Swedish Trial in Old Patients with Hypertension (STOP-Hypertension). Lancet 1991, 338:1281-1285.
35. MRC Working Party Medical research council trial of treatment of hypertension in older adults: principal results. BMJ 1992, 304:405-412.
36. Cutler JA, MacMahon SW, Furberg CD Controlled clinical trials of drug treatment for hypertension: A review. Hypertension 1989, 13(I):I-36-I-44.
37. Collins R, Peto R, MacMahon SW, et al. Blood pressure, stroke, and CHD: II. Short-term reductions in blood pressure: Overview of randomized drug trials in their epidemiological context. Lancet 1990, 335:827-838.
38. Hebert PR, Moser M, Mayer J, et al. Recent evidence on drug therapy of mild to moderate hypertension and decreased risk of CHD. Arch Intern Med 1993, 153:578-581.
39. Collins R, MacMahon S Blood pressure, antihypertensive drug treatment and the risks of stroke and of CHD. Br Med Bull 1994, 50:272-298.
40. Lipid Research Clinics Program The Lipid Research Clinics Coronary Primary Prevention Trial results: I. Reduction in incidence of CHD. JAMA 1984, 251:351-364.
41. Frick MH, Elo O, Haapa K, et al. Helsinki Heart Study: Primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia: Safety of treatment, changes in risk factors, and incidence of CHD. N Engl J Med 1987, 317:1237-1245.
42. Multiple Risk Factor Intervention Trial Research Group Mortality rates after 10.5 years for participants in the Multiple Risk Factor Intervention Trial: Findings related to a priori hypotheses of the trial. JAMA 1990, 263:1795-1801.
43. IPPPSH Collaborative Group Cardiovascular risk and risk factors in a randomized trial of treatment based on the beta-blocker oxprenolol: The International Prospective Primary Prevention Study in Hypertension (IPPPSH). J Hypertens 1985, 3:379-392.
44. Wilhelmsen L, Berglund G, Elmfeldt D, et al. Beta-blockers versus diuretics in hypertensive men: Main results from the HAPPHY trial. J Hypertens 1987, 5:561-572.
45. The seventh in JAMA report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med 1997, 157:2413-2446.
46. Kaplan NM, Gifford RW Choice of initial therapy for hypertension. JAMA 1996, 275:1577-1580.
47. Dzau VJ Tissue angiotensin and pathobiology of vascular disease: A unifying hypothesis. Hypertension 2001, 37:1047-1052.
48. Manolio TA, Cutler JA, Furberg CD, et al. Trends in pharmacologic management of hypertension in the United States. Arch Intern Med 1995, 155:829-837.
49. Blood Pressure Lowering Treatment Trialists' Collaboration Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: Results of prospectively designed overviews of randomised trials. Lancet 2000, 355:1955-1964.
50. Pahor M, Psaty BM, Alderman MH, et al. Health outcomes associated with calcium antagonists compared with other first-line antihypertensive therapies: A meta-analysis of randomised controlled trials. Lancet 2000, 355:1949-1954.
51. Staessen JA, Wang J-G, Thijs L Cardiovascular protection and blood pressure reduction: A meta-analysis. Lancet 2001, 358:1305-1315.
52. HOPE (Heart Outcomes Prevention Evaluation) Study Investigators Effects of an angiotensin-converting-enzyme-inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000, 342:145-153.
53. MacMahon S, Sharpe N, Gamble G, et al. Randomized, placebo-controlled trial of an angiotensin-converting enzyme inhibitor, ramipril, in patients with coronary or other occlusive arterial disease. J Am Coll Cardiol 2000, 36:438-443.
54. Cashin-Hemphill L, Holmvang G, Chan R, et al. Angiotensin converting enzyme inhibition as antiatherosclerotic therapy: No answer yet. Am J Cardiol 1999, 83:43-47.
55. Teo KK, Burton JR, Buller CE, et al. Long-term effects of cholesterol lowering and angiotensin-converting enzyme inhibition on coronary atherosclerosis: The Simvastatin/Enalapril Coronary Atherosclerosis Trial (SCAT). Circulation 2000, 102:1748-1754.
56. Pitt B, Byington RP, Furberg CD, et al. Effect of amlodipine on the progression of atherosclerosis and the occurrence of clinical events: PREVENT Investigators. Circulation 2000, 102:1503-1510.
57. Staessen JA, Fagard R, Thijs L, et al. Randomized double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension: The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Lancet 1997, 350:757-764.
58. Hansson L, Lindholm LH, Niskanen L, et al. Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: The Captopril Prevention Project (CAPPP) randomised trial. Lancet 1999, 353:611-616.
59. Hansson L, Lindholm LH, Ekbom T, et al. Randomised trial of old and new antihypertensive drugs in elderly patients: Cardiovascular mortality and morbidity: The Swedish Trial in Old Patients with Hypertension-2 study. Lancet 1999, 354:1751-1756.
60. UK Prospective Diabetes Study Group Efficacy of atenolol and cap-topril in reducing risk of macrovascular and microvascular complications in type two diabetes: UKPDS 39. BMJ 1998, 317:713-720.
61. Brown MJ, Palmer CR, Castaigne A, et al. Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT). Lancet 2000, 356:366-372.
62. National Intervention Cooperative Study in Elderly Hypertensives Study Group Randomized double-blind comparison of a calcium antagonist and a diuretic in elderly hypertensives. Hypertension 1999, 34:1129-1133.
63. Hansson L, Hedner T, Lund-Johansen P, et al. Randomised trial of effects of calcium antagonists compared with diuretics and beta-blockers on cardiovascular morbidity and mortality in hypertension: The Nordic Diltiazem (NORDIL) study. Lancet 2000, 356:359-365.
64. Agabiti Rosei E, Dal Palu C, Leonetti G, et al. Clinical results of the Verapamil in Hypertension and Atherosclerosis Study. J Hypertens 1997, 15:1337-1344.
65. Zanchetti A, Rosei EA, Dal Palu C, et al. The Verapamil in Hypertension and Atherosclerosis Study (VHAS): results of long-term randomized treatment with either verapamil or chlorthalidone on carotid intima-media thickness. J Hypertens 1998, 16:1667-1676.
66. Estacio RO, Jeffers BW, Hiatt WR, et al. The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin dependent diabetes and hypertension. N Engl J Med 1998, 338:645-652.
67. Hansson L, Zanchetti A, Carruthers SG, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: Principal results of the Hypertension Optimal Treatment (HOT) randomized trial. HOT Study Group. Lancet 1988, 351:1755-1762.
68. UK Prospective Diabetes Study Group Tight blood pressure control and risk of macrovascular and microvascular complications in type-2 diabetes. UKPDS 37. BMJ 1998, 317:703-713.
69. PROGRESS Collaborative Group Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient ischemic attack. Lancet 2001, 358:1033-1041.
70. Dahlof B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002, 359:995-1003.
71. Stumpe KO, Ludwig M, Heagerty AM, et al. Vascular wall thickness in hypertension: The perindopril regression of vascular thickening European Community trial (PROTECT). Am J Cardiol 1995, 76:50E-54E.
72. Casiglia E, Spolaore P, Mazza A, et al. Effect of two different therapeutic approaches on total and cardiovascular mortality in a cardiovascular study in the elderly (CASTEL). Jpn Heart J 1994, 35(270):713-724.
73. Tatti P, Pahor M, Byington RP, et al. Outcome results of the Fosinopril versus Amlodipine Cardiovascular Events randomized Trial (FACET) in patients with hypertension and NIDDM. Diabetes Care 1998, 21:560-597.
74. Borhani NO, Mercuri M, Borhani PA, et al. Final outcome results of the Multicenter Isradipine Diuretic Atherosclerosis Study (MIDAS): A randomized controlled trial. JAMA 1996, 276:785-791.
75. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2000, 283:1967-1975.
76. He J, Whelton PK Selection of initial antihypertensive drug therapy. Lancet 2000, 356:1942-1943.
77. Davis BR, Cutler JA, Gordon DJ, et al. Rationale and design for the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).Am J Hypertens 1996, 9:342-360.
78. The ALLHAT Officers and Coordinators for the ALLHAT Investigative Research Group Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002, 288:2981-2997.
79. Wing LMH, Reid CM, Ryan P, et al. A comparison of outcomes with angiotensin-converting-enzyme inhibitors and diuretics for hypertension in the elderly. N Engl J Med 2003, 348:583-592.
80. Black HR, Elliott WJ, Grandits G, et al. Principal results of the controlled onset verapamil investigation of cardiovascular end points (CONVINCE) trial. JAMA 2003, 289:2073-2082.
81. Blood Pressure Lowering Treatment Trialists' Collaboration Effects of different blood-pressure-lowering regimens in cardiovascular events: Results of prospectively-designed overviews of randomised trials. Lancet 2003, 362:1527-1535.
82. Psaty BM, Lumley T, Furberg CD, et al. Health outcomes associated with various antihypertensive therapies used as first-line agents: A network meta-analysis. JAMA 2003, 2534-2544.
83. Sever PS, Dahlof B, Poulter NR, et al. Rationale, design, methods and baseline demography of participants of the Anglo-Scandinavian Cardiac Outcomes Trial. ASCOT investigators. J Hypertens 2001, 19:1139-1147.
84. Frohlich ED Reappearance of the J-shaped curve. Hypertension 1999, 34:1179-1180.
85. Coresh J, Whelton PK, Mead LA, et al. Increased cardiovascular disease risk in treated hypertensive men. J Hypertens 1994, 12(3):S73.
86. Lindholm L, Ejlertsson G, Scherstein B High risk of cerebrocardiovascular morbidity in well treated male hypertensives: A retrospective study of 40-59-year-old hypertensives in a Swedish primary care district. Acta Med Scand 1984, 216:251-259.
87. Samuelsson O Hypertension in middle-aged men: management, morbidity and prognostic factors during long-term hypertensive care. Acta Med Scand 1985, 218(702):1-79.
88. Isles CG, Walker LM, Beevers DG, et al. Mortality in patients of the Glasgow Blood Pressure Clinic. J Hypertens 1986, 4:141-156.
89. Wright JT, Bakris GL, Green T, et al. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: Results from the AASK trial. JAMA 2002, 288:2421-2431.
90. Agodoa LY, Appel LJ, Bakris GL, et al. Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: A randomized controlled trial. JAMA 2001, 285:2719-2728.
91. Chalmers J, MacMahon S, Mancia G, et al. 1999 World Health Organization-International Society of Hypertension Guidelines for the management of hypertension. Guidelines sub-committee of the World Health Organization. Clinical & Experimental Hypertension 1999, 21:1009-1060.
92. Whelton PK, He J, Appel LJ, et al. Primary prevention of hypertension: Clinical and public health advisory from the National High Blood Pressure Education Program. JAMA 2002, 288:1882-1888.